

**Provocative Questions Exploratory Meeting**  
**October 9, 2010**  
**National Cancer Institute**  
**Building 60, The Cloisters**  
**Bethesda, Maryland**

**Co-Chairs**

**Harold Varmus, MD**

Director  
National Cancer Institute  
Bethesda, MD

**Douglas Lowy, MD**

Deputy Director  
National Cancer Institute  
Bethesda, MD

**Edward Harlow, PhD**

Chief Scientific Officer  
Constellation Pharmaceuticals  
Cambridge, MA

**Tyler Jacks, PhD**

Director, David H. Koch Institute  
for Integrative Cancer Research  
Koch Institute at MIT  
Cambridge, MA

**Participants**

**Dafna Bar-Sagi, PhD**

Professor and Chair  
Department of Biochemistry  
NYU School of Medicine  
New York, NY

**Andrea Califano, PhD**

Professor of Systems Biology  
Director, Columbia Initiative in  
Systems Biology  
Director, Columbia Genome Center  
Associate Director, Herber Irving  
Comprehensive Cancer Center  
New York, NY

**Lewis Cantley, PhD**

Director, Cancer Center at Beth  
Israel  
Deaconess Medical Center  
Professor, Systems Biology  
Harvard Medical School  
Beth Israel Deaconess  
Medical Center  
Boston, MA

**Arul Chinnaiyan, MD, PhD**

Michigan Center for Translational  
Pathology  
University of Michigan  
Ann Arbor, MI

**Karen Cichowski, PhD**

Assistant Professor  
Harvard Medical School and  
Brigham and Women's Hospital  
Boston, MA

**Lawrence Corey, MD**

Senior Vice President  
Fred Hutchinson Cancer  
Research Center  
Seattle, WA

**Robert Croyle, PhD**

Director  
Division of Cancer Control and  
Population Sciences  
National Cancer Institute  
Bethesda, MD

**Titia de Lange, PhD**

Leon Hess Professor  
American Cancer Society Professor  
Head, Laboratory of Cell Biology  
and Genetics  
Associate Director, Anderson  
Cancer Center  
Rockefeller University  
New York, NY

**James Doroshow, MD**

Director  
Division of Cancer Therapy  
and Diagnosis  
National Cancer Institute  
Bethesda, MD

**Glenn Dranoff, MD**

Associate Professor of Medicine  
Dana-Farber Cancer Institute and  
Harvard Medical School  
Leader, Dana-Farber/Harvard  
Cancer Center Program in Cancer  
Immunology  
Boston, MA

**D. Gary Gilliland, MD PhD**

Senior Vice President Franchise  
Head Oncology  
Merck & Co., Inc.  
North Wales, PA

**William G. Kaelin, Jr., MD**

Howard Hughes Medical Institute  
Dana Farber Cancer Institute  
Boston, MA

**Marc Kirschner, Ph.D.**

John Franklin Enders  
University Professor  
Chair and Professor of  
Systems Biology  
Harvard Medical School  
Boston, MA

**Jennifer A. Pietenpol, PhD**

Director, Vanderbilt-Ingram  
Cancer Center  
B.F. Byrd Jr. Professor of Oncology  
Professor of Biochemistry, Cancer  
Biology and Otolaryngology  
Vanderbilt University School  
of Medicine  
Nashville, TN

**Charles Sawyers, MD**

Chairman  
Human Oncology and  
Pathogenesis Program  
Memorial Sloan-Kettering  
Cancer Center  
New York, NY

**Kevan Shokat, Ph.D.**

Professor and Chair  
Department of Cellular and  
Molecular Pharmacology  
University of California  
San Francisco  
San Francisco, CA

**Dinah Singer, PhD**

Director  
Division of Cancer Biology  
National Cancer Institute  
Bethesda, MD

**Margaret R. Spitz, MD**

Professor and  
Cielito Reyes-Gibby, Dr.PH  
Associate Professor  
Department of Epidemiology  
MD Anderson Cancer Center  
Houston, TX

**Louis Staudt, MD, PhD**

Head, Molecular Biology of  
Lymphoid Malignancies Section  
Metabolism Branch  
National Cancer Institute  
Bethesda, MD

**Craig Thompson, MD**

Director, Abramson Cancer Center  
University of Pennsylvania School  
of Medicine  
Philadelphia, PA

**Irv Weissman, MD**

Director, Institute for Stem Cell  
Biology and Regenerative Medicine  
Stanford University  
Stanford, CA

**Eileen White, PhD**

Associate Director for Basic Science  
The Cancer Institute of New Jersey  
Professor, Molecular Biology  
and Biochemistry  
Rutgers University  
Program Leader, Cancer Institute of  
New Jersey  
New Brunswick, NJ